Aspire BioPharma is trading 12.04% down at $7.20, amid a U.S. market selloff after hotter-than-expected September inflation revived higher-rate expectations; no clear company-specific catalyst was identified for October 14, 2026.
- Reuters reported that CPI data pressured stocks; XBI fell 2.01%, adding biotech-sector context.
- The company’s press-release page listed no new announcement for the session, and available search results did not establish a direct company catalyst.